Volume 26, Number 5—May 2020
Synopsis
Epidemiology of Tick-Borne Relapsing Fever in Endemic Area, Spain
María Carmen Domínguez
, Salvador Vergara, María Carmen Gómez, and María Esther Roldán
, Salvador Vergara, María Carmen Gómez, and María Esther Roldán
Table 2
Main symptoms, signs, and analytical findings of 98 patients with tick-borne relapsing fever, Spain*
| Variable | Value | |
|---|---|---|
| Symptoms | ||
| Fever >38.5°C | 97 (99) | |
| Headache | 58 (59) | |
| Vomiting | 34 (34.7) | |
| Arthralgia | 29 (30) | |
| Abdominal pain | 28 (28.6) | |
| Myalgia | 28 (28.6) | |
| Chills | 23 (23.6) | |
| Diarrhea |
6 (6.1) |
|
| Signs | ||
| Meningeal signs | 7 (7.1) | |
| Splenomegaly | 7 (7.1) | |
| Hepatomegaly | 6 (6.1) | |
| Exanthema | 4 (4.1) | |
| Jaundice | 3 (3.1) | |
| Petechiae | 2 (2) | |
| Conjunctival injection |
2 (2) |
|
| Analytical findings | ||
| Median platelet count, × 103/mm3 (IQR) | 63.5 (45.7–87.5) | |
| Thrombocytopenia, platelets <13 × 104/mm3 | 91 (92.9) | |
| Hemoglobin, g/dL (IQR) | 13.1 (11.8–14.2) | |
| Anemia | 32 (32.6) | |
| Leukocytes, ×103/mm3 (IQR) | 7.9 (6.6–9.8) | |
| Leukocytosis, >11,500/mm3 | 10 (10.2) | |
| Neutrophils, median (IQR) | 79.9 (74.5–86.4) | |
| Neutrophilia, neutrophils >65% | 91 (92.9) | |
| Prothrombin activity, median (IQR) | 77 (70–87) | |
| Decreased prothrombin activity, <70% | 7 (13.7) | |
| Median INR (IQR) | 1.2 (1.1–1.3) | |
| INR elevation, >1.51 | 7 (13.7) | |
| SGOT, U/L (IQR) | 25 (20–35) | |
| SGOT elevation, >37 U/L | 15 (21.7) | |
| SGPT, U/L (IQR) | 25 (17–41) | |
| SGPT elevation, >40 U/L | 10 (23.3) | |
| Total bilirubin, mg/dL (IQR) | 1.1 (0.6–1.9) | |
| Elevated bilirubin, >1.2 mg/dL | 37 (37.8) | |
| Lactate dehydrogenase, U/L(IQR) | 397.5 (320.7–481.7) | |
| Elevated LDH, >460 U/L | 16 (30.8) | |
| Creatinine, mg/dL (IQR) | 0.94 (0.79–1.15) | |
| Creatinine elevation, >1.2 mg/dL | 15 (15.3) | |
| Creatine kinase, U/L (IQR) | 41 (27–75) | |
| Elevated creatine kinase, >195 U/L | 3 (14) | |
| C-reactive protein, mg/L (IQR) | 254.5 (218.2–335.3) | |
| Elevated C-reactive protein, >5 mg/L |
98 (100) |
|
| *Values are no. (%) except as indicated. INR, international normalized ratio; IQR, interquartile range; SGOT, serum glutamic-oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase. | ||
Page created: April 16, 2020
Page updated: April 16, 2020
Page reviewed: April 16, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.